Optimizing Dosing Strategies for Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how evolving dosing strategies are helping improve the real-world use of BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).

The conversation focuses on the transition from intensive early dosing schedules to less frequent administration as patients achieve deep and durable responses.

Dr. Mewawalla shares her clinical experience individualizing dosing intervals based on treatment response, depth of remission, and tolerability, while emphasizing the importance of sustained complete responses when considering dose spacing.

The faculty also discuss how rapid responses observed with bispecific antibodies may support treatment optimization strategies aimed at reducing treatment burden and potentially mitigating long-term toxicities, including infections.

In addition, the panel highlights ongoing clinical questions regarding treatment duration, the possibility of time-limited therapy, and whether some patients may maintain durable disease control with reduced treatment intensity.

The segment underscores how dosing flexibility is becoming an important component of RRMM management in contemporary practice.